問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital

Division of Urology

Division of Radiology

更新時間：2025-10-18

姜伯璋
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

3Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

姜伯璋

List

3Cases

2025-09-15 - 2036-04-30

Phase III

Not yet recruiting
A randomized, double-blind, placebo-controlled phase III trial is evaluating adjuvant saruparib (AZD5305) (EvoPAR-Prostate02) in patients with locally high-risk prostate cancer of the breast cancer gene mutation (BRCAm) who are currently receiving radiation therapy and androgen deprivation therapy.

  • Condition/Disease

    Metastasis-free survival (MFS) [Time range: approximately 93 months] - MFS is defined as the time elapsed from the date of randomization until the day of first diagnosis of distant metastasis as assessed by BICR (confirmed by standard clinical imaging [CT/MRI and bone scan, or PSMA-PET]) or death from any cause.

  • Test Drug

    AZD5305

Participate Sites
8Sites

Recruiting8Sites

2025-07-01 - 2029-02-12

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2025-08-01 - 2032-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB